Obio Technology Shanghai Corp

Obio Technology Shanghai Corp Interest Coverage

The Interest Coverage Ratio of Obio Technology Shanghai Corp (688238.SS) as of Oct 30, 2026 is -4,256.62. In the previous year, Interest Coverage Ratio was -10.35 — a change of 41,022.40% (lower).

Interest Coverage

-4,256.62

YoY

41,022.40%

Last updated:

Interest Coverage Ratio of Obio Technology Shanghai Corp is 2024 -4,256.62 . Interest Coverage Ratio of Obio Technology Shanghai Corp was 2023 -10.35 . It decreases by 41,022.40% lower compared to the previous year.

The Obio Technology Shanghai Corp Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
-724.69 CNY
Jan 1, 2019
-18.26 CNY
Jan 1, 2021
4.23 CNY
Jan 1, 2022
0.50 CNY
Jan 1, 2023
-10.35 CNY
Jan 1, 2024
-4,256.62 CNY
The Obio Technology Shanghai Corp Interest Coverage history
YEARInterest CoverageYoY
-4,256.62+41,022.40%
-10.35-2,158.59%
0.50-88.11%
4.23-123.15%
-18.26-97.48%
-724.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Obio Technology Shanghai Corp Stock analysis

What does Obio Technology Shanghai Corp do? Obio Technology Shanghai Corp Ltd provides biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO services. The company offers contract research organization (CRO) services including gene therapy vector development and gene function research for gene therapy basic research, as well as contract research and development production organization (CDMO) services for gene drug R&D, such as pharmaceutical research and clinical sample production. It serves European and American markets and the domestic market with its CRO and CDMO offerings. The firm generates revenue through CRO services like gene therapy vector development and gene function research, and CDMO services including pharmaceutical research and clinical sample production. Its primary clients are companies involved in gene therapy and gene drug development, focusing on the European and American markets and domestic segments. The company's services support the research and development phases of gene therapy and gene drug products. Obio Technology Shanghai Corp Ltd's business model centers on providing specialized research and production services for gene therapy and gene drug development. By offering both CRO and CDMO services, it addresses key needs in the gene therapy industry, particularly in vector development and clinical sample production, targeting pharmaceutical companies and research institutions in Europe, America, and China. Obio Technology Shanghai Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obio Technology Shanghai Corp stock

Interest Coverage Ratio of Obio Technology Shanghai Corp is -4,256.62 in 2024.

Interest Coverage Ratio of Obio Technology Shanghai Corp changed from -10.35 to -4,256.62, representing a 41,022.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Obio Technology Shanghai Corp since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Obio Technology Shanghai Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Obio Technology Shanghai Corp

All Key Metrics — Obio Technology Shanghai Corp